Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 4/20 | 0.60 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.60 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.60 |
| ▸ | HSD11B1 | P28845 | 9/20 | 0.52 |
| ▸ | CCR2 | P41597 | 2/20 | 0.45 |
| ▸ | AXL | P30530 | 2/20 | 0.43 |
| ▸ | ATR | Q13535 | 1/20 | 0.43 |
| ▸ | ATRIP | Q8WXE1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20111623 | 0.89 | OPRL1 (0.56) | OPRL1OPRM1OPRK1HSD11B1CCR2 | |
| SCHEMBL20111641 | 0.87 | OPRL1 (0.54) | OPRL1OPRM1OPRK1HSD11B1CCR2 | |
| SCHEMBL21714371 | 0.87 | OPRL1 (0.56) | OPRL1OPRM1OPRK1HSD11B1CCR2 | |
| SCHEMBL20112228 | 0.86 | OPRL1 (0.53) | OPRL1OPRM1OPRK1HSD11B1AXL | |
| SCHEMBL21714204 | 0.86 | OPRL1 (0.53) | OPRL1OPRM1OPRK1HSD11B1CCR2 | |
| SCHEMBL21714645 | 0.86 | OPRL1 (0.53) | OPRL1OPRM1OPRK1HSD11B1CCR2 | |
| SCHEMBL18324723 | 0.85 | OPRL1 (0.59) | OPRL1OPRM1OPRK1HSD11B1AXL | |
| SCHEMBL23153236 | 0.85 | HSD11B1 (0.56) | OPRL1OPRM1OPRK1HSD11B1CCR2 | |
| SCHEMBL20111763 | 0.85 | OPRL1 (0.53) | OPRL1OPRM1OPRK1HSD11B1CCR2 | |
| SCHEMBL21714511 | 0.85 | OPRL1 (0.51) | OPRL1OPRM1OPRK1HSD11B1CCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200055847-A1 | MODULATORS OF HEDGEHOG (HH) SIGNALLING PATHWAY | E-THERAPEUTICS PLC (GB) | 2020-02-20 | — | — | US | claimed |
| US-10961238-B2 | Modulators of hedgehog (Hh) signaling pathway | E-THERAPEUTICS PLC (GB) | 2021-03-30 | — | — | US | disclosed |
| US-10961238-B2 | Modulators of hedgehog (Hh) signaling pathway | E-THERAPEUTICS PLC (GB) | 2021-03-30 | — | — | US | disclosed |
| US-20200055847-A1 | MODULATORS OF HEDGEHOG (HH) SIGNALLING PATHWAY | E-THERAPEUTICS PLC (GB) | 2020-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10961238-B2 | Modulators of hedgehog (Hh) signaling pathway | SHH, GLI1, SMO | OPRL1 3722/4885OPRM1 2285/4885OPRK1 2423/4885 |
| US-20200055847-A1 | MODULATORS OF HEDGEHOG (HH) SIGNALLING PATHWAY | SHH, GLI1, SMO | OPRL1 3657/4885OPRM1 2365/4885OPRK1 2508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.